Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation.

Antimicrobial Agents and Chemotherapy
Kabir SardanaShamik Ghosh

Abstract

Recalcitrant dermatophytic infections of the glabrous skin (tinea corporis/cruris/faciei) pose a huge challenge to health care systems. Combinations of oral and topical drugs may potentially improve cure rates, but the same has never been objectively assessed for this condition in laboratory or clinical studies. The present study was undertaken with the aim of identifying synergistic combinations of oral and topical antifungals by testing clinical isolates obtained from patients with recalcitrant tinea corporis/cruris. Forty-two patients with tinea corporis/cruris who had failed oral antifungals or had relapsed within 4 weeks of apparent clinical cure were recruited. Twenty-one isolates were identified by sequencing (all belonging to the Trichophyton mentagrophytes/T. interdigitale species complex) and subjected to antifungal susceptibility testing (AFST) and squalene epoxidase (SQLE) gene mutation analysis. Finally, five isolates, four with underlying SQLE gene mutations and one wild-type strain, were chosen for checkerboard studies using various combinations of antifungal agents. Most isolates (n = 16) showed high MICs of terbinafine (TRB) (0.5 to >16 μg/ml), with SQLE gene mutations being present in all isolates with MICs of...Continue Reading

References

Jul 1, 1972·Antimicrobial Agents and Chemotherapy·J J KabaraJ P Truant
Sep 2, 2000·Journal of Clinical Microbiology·S PereaA del Palacio
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Melissa D JohnsonJohn H Rex
Jun 19, 2004·The Journal of Dermatological Treatment·S HarmanE G V Evans
Apr 9, 2005·Journal of Clinical Microbiology·D A Santos, J S Hamdan
Feb 7, 2015·Indian Journal of Medical Microbiology·A LakshmananR Madhavan
Mar 14, 2018·Antimicrobial Agents and Chemotherapy·Shivaprakash M RudramurthyArunaloke Chakrabarti
Sep 27, 2018·Biocontrol Science·Shusaku SuzukiKatsumi Fujitani
Feb 16, 2019·The Journal of Dermatology·Junichiro HirumaKazutoshi Harada
Apr 7, 2019·Expert Review of Clinical Pharmacology·Kabir SardanaAastha Gupta
May 18, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Anke SüßPietro Nenoff
Jul 23, 2019·Fungal Genetics and Biology : FG & B·Ananta KhuranaAnuradha Chowdhary
Jul 25, 2019·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Yoon Seol Bae, Min Suk Rhee
Dec 7, 2019·Indian Dermatology Online Journal·Ananta KhuranaKhushboo Sethia
Feb 3, 2020·Journal of Global Antimicrobial Resistance·Heather DavisGeorge Pankey

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
electrophoresis
scrapings

Software Mentioned

BLAST

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.